Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | ALK tyrosine kinase receptor | ||
Ligand | BDBM50396269 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | ChEMBL_863887 (CHEMBL2176371) | ||
IC50 | 3±n/a nM | ||
Citation | Lewis, RT; Bode, CM; Choquette, DM; Potashman, M; Romero, K; Stellwagen, JC; Teffera, Y; Moore, E; Whittington, DA; Chen, H; Epstein, LF; Emkey, R; Andrews, PS; Yu, VL; Saffran, DC; Xu, M; Drew, A; Merkel, P; Szilvassy, S; Brake, RL The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer. J Med Chem55:6523-40 (2012) [PubMed] Article | ||
More Info.: | Get all data from this article, Assay Method | ||
ALK tyrosine kinase receptor | |||
Name: | ALK tyrosine kinase receptor | ||
Synonyms: | ALK | ALK tyrosine kinase receptor (ALK) | ALK_HUMAN | Anaplastic lymphoma kinase | CD_antigen: CD246 | ||
Type: | Protein | ||
Mol. Mass.: | 176453.10 | ||
Organism: | Homo sapiens (Human) | ||
Description: | Q9UM73 | ||
Residue: | 1620 | ||
Sequence: |
| ||
BDBM50396269 | |||
n/a | |||
Name | BDBM50396269 | ||
Synonyms: | CHEMBL2172320 | ||
Type | Small organic molecule | ||
Emp. Form. | C34H43FN6O3 | ||
Mol. Mass. | 602.742 | ||
SMILES | CC(C)NC(=O)[C@H]1CC[C@H](CC1)n1c(NC(=O)c2cc(F)cc(c2)C#N)nc2ccc(CN3CCC(CC3)C(C)(C)O)cc12 |r,wU:9.12,6.5,(21.82,-55.64,;20.32,-55.32,;19.84,-53.86,;19.29,-56.47,;17.78,-56.15,;16.75,-57.3,;17.3,-54.69,;15.8,-54.37,;15.32,-52.91,;16.35,-51.77,;17.85,-52.07,;18.33,-53.54,;15.86,-50.31,;16.77,-49.05,;18.31,-49.04,;19.07,-47.7,;18.29,-46.37,;20.61,-47.69,;21.36,-46.35,;22.9,-46.34,;23.66,-45,;23.68,-47.67,;22.92,-49.01,;21.38,-49.02,;23.7,-50.33,;24.47,-51.66,;15.85,-47.8,;14.38,-48.28,;13.04,-47.52,;11.71,-48.29,;11.71,-49.84,;10.38,-50.6,;9.05,-49.83,;9.05,-48.29,;7.73,-47.52,;6.39,-48.29,;6.39,-49.83,;7.72,-50.61,;5.05,-47.51,;4.28,-46.17,;5.82,-46.16,;3.72,-48.27,;13.05,-50.61,;14.39,-49.84,)| | ||
Structure |